Trial · NCT04603495
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pelabresib + Ruxolitinib (Experimental Arm) | 214 | |
| Overall Study | STARTED | Placebo + Ruxolitinib (Control Arm) | 216 | |
| Overall Study | Modified Intent-to-Treat (mITT) Analysis Set | Pelabresib + Ruxolitinib (Experimental Arm) | 212 | |
| Overall Study | Modified Intent-to-Treat (mITT) Analysis Set | Placebo + Ruxolitinib (Control Arm) | 214 | |
| Overall Study | Safety Analysis Set | Pelabresib + Ruxolitinib (Experimental Arm) | 212 | |
| Overall Study | Safety Analysis Set | Placebo + Ruxolitinib (Control Arm) | 214 | |
| Overall Study | Per-Protocol Set (PP Set) | Pelabresib + Ruxolitinib (Experimental Arm) | 196 | |
| Overall Study | Per-Protocol Set (PP Set) | Placebo + Ruxolitinib (Control Arm) | 194 | |
| Overall Study | Pharmacokinetic (PK) Analysis Set | Pelabresib + Ruxolitinib (Experimental Arm) | 212 | |
| Overall Study | Pharmacokinetic (PK) Analysis Set | Placebo + Ruxolitinib (Control Arm) | 211 | |
| Overall Study | Biomarker Analysis Set | Pelabresib + Ruxolitinib (Experimental Arm) | 212 | |
| Overall Study | Biomarker Analysis Set | Placebo + Ruxolitinib (Control Arm) | 214 | |
| Overall Study | Ongoing on Double-blind Treatment | Pelabresib + Ruxolitinib (Experimental Arm) | 154 | |
| Overall Study | Ongoing on Double-blind Treatment | Placebo + Ruxolitinib (Control Arm) | 160 | |
| Overall Study | Discontinued Double-blind Treatment | Pelabresib + Ruxolitinib (Experimental Arm) | 58 | |
| Overall Study | Discontinued Double-blind Treatment | Placebo + Ruxolitinib (Control Arm) | 54 | |
| Overall Study | On PFS/OS Follow-up | Pelabresib + Ruxolitinib (Experimental Arm) | 22 | |
| Overall Study | On PFS/OS Follow-up | Placebo + Ruxolitinib (Control Arm) | 30 | |
| Overall Study | COMPLETED | Pelabresib + Ruxolitinib (Experimental Arm) | 181 | |
| Overall Study | COMPLETED | Placebo + Ruxolitinib (Control Arm) | 193 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04603495/flow